Ben Locwin is a healthcare executive and has been working on various COVID-19 Task Forces and committees, at the Federal and State levels, for epidemiology and directing of Public Health initiatives. He was the first to suggest focusing on aerosol and asymptomatic transmission of SARS-CoV-2, and to undo the reliance on the symbolic theater of surface cleaning.
His work has involved bringing new and innovative medical treatments (drug therapies, vaccines, and medical devices) to patient populations with unmet needs across a variety of indications and health conditions. This includes clinical assessment of patients, overseeing diverse clinical trials, and working with investors on the ‘next big things’ in the industry. He has been featured in The Wall Street Journal, Forbes, USA Today, and other top-tier media. His recent concern has been on de-bottlenecking the FDA, EMA, MHRA, and other regulatory bodies so that the next wave of therapies can be brought to bear for the public’s benefit.